|1.||Wei, Yuhui: 1 article (12/2014)|
|2.||Zhou, Yan: 1 article (12/2014)|
|3.||Zhang, Jianping: 1 article (12/2014)|
|4.||Wu, Xinan: 1 article (12/2014)|
|5.||Zhang, Fan: 1 article (12/2014)|
|6.||Zhou, Liting: 1 article (12/2014)|
|7.||Wang, Dan: 1 article (12/2014)|
|8.||Zeng, Caiwen: 1 article (03/2014)|
|9.||Xia, Chunhua: 1 article (03/2014)|
|10.||Huang, Shibo: 1 article (03/2014)|
|1.||Diabetic Nephropathies (Diabetic Nephropathy)
02/01/2014 - "The efficacy of gliquidone for the treatment of diabetic nephropathy was investigated by implanting micro-osmotic pumps containing gliquidone into the abdominal cavities of Goto-Kakizaki (GK) rats with diabetic nephropathy. "
02/01/2014 - "In conclusion, gliquidone treatment effectively reduced urinary protein in GK rats with diabetic nephropathy by improving glomerular lesions and promoting tubular reabsorption. "
02/01/2014 - "Gliquidone lowered blood glucose, 24 h urinary protein, and 24 h urinary albumin levels in GK rats with diabetic nephropathy. "
12/01/2014 - "Huangqi injection (HI), a common preparation of Huang Qi, was wildly co-administered with gliquidone to treat diabetes mellitus and diabetic nephropathy in clinic of China. "
|3.||Type 2 Diabetes Mellitus (MODY)
07/01/2006 - "Gliquidone is a second generation sulfonyleurea derivative, indicated to improve glycemic control in NIDDM patients. "
01/01/2006 - "Gliquidone contributes to improvement of type 2 diabetes mellitus management: a review of pharmacokinetic and clinical trial data."
12/01/1997 - "We concluded that gliquidone is an effective oral hypoglycemic agent for treating patients with NIDDM. "
07/01/1993 - "[Glurenorm in the treatment of patients with non-insulin-dependent diabetes mellitus with diseases of the liver and bile ducts]."
05/01/1993 - "The results evidence no negative effects of glurenorm on the kidneys or liver, therefore the drug may be used in the treatment of NIDDM patients with liver abnormalities."
01/01/1992 - "In the present study we evaluated the effects of gliquidone, a second-generation compound, on several metabolic parameters in 22 patients with untreated newly-diagnosed type II (noninsulin-dependent) diabetes mellitus. "
07/01/1995 - "[The use of the hypoglycemic preparation gliquidone in patients with digestive organ diseases combined with diabetes mellitus]."
03/01/1993 - "[A comparative evaluation of the effect of glurenorm and sulfonylurea preparations on the intravascular microcirculatory indices in type-II diabetes mellitus]."
03/01/2014 - "7. These findings may assist in valuable prediction of potential interactions of gliquidone with other drugs that are CYP3A4 inhibitors or inducers and help to design more efficacious and safer pharmacotherapy for patients of diabetes mellitus."
07/01/2008 - "Gliquidone therapy of new-onset diabetes mellitus after kidney transplantation."
|5.||Body Weight (Weight, Body)
04/23/1997 - "The monoethyl, monopropyl and monoisopropyl esters of succinic acid, administered intravenously at the dose of 2 micromol/g body weight, were found to increase the insulinotropic action of gliquidone (0.2 nmol/g body weight) in anaesthetized rats. "
04/01/1983 - "A study was made of the effects of acute or chronic treatment of rabbits with 10 mg gliquidone (Glurenorm)/kg body weight on erythrocyte insulin receptors. "
|2.||Drug Therapy (Chemotherapy)